2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(1-{4-[(E)-2-(2,4-dihydroxyphenyl)ethenyl]-2,6-dihydroxyphenyl}-3-hydroxy-3-methylbutan-2-yl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid

Metabolite details

Identifier

YOOGLPFQFRFMSU-ONEGZZNKSA-N

InChI Key

YOOGLPFQFRFMSU-ONEGZZNKSA-N

IUPAC name

2-amino-5-[[1-(carboxymethylamino)-3-[1-[4-[(E)-2-(2,4-dihydroxyphenyl)ethenyl]-2,6-dihydroxyphenyl]-3-hydroxy-3-methylbutan-2-yl]sulanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid

Preferred name

2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(1-{4-[(E)-2-(2,4-dihydroxyphenyl)ethenyl]-2,6-dihydroxyphenyl}-3-hydroxy-3-methylbutan-2-yl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid

INN name

—

Synonym

—

ChEBI

CHEBI:190888

Reactome pathways

• No Reactome pathways listed for this metabolite.

Observed in studies

• Bioaccumulation of therapeutic drugs by human gut bacteria: cross-feeding metabolite analysis (FIA-MS) (E.rectale;S.salivarius assays)

Observed in differential profiles

• G4_Eubacterium_rectale_DMSO_30_vs_G3_Eubacterium_rectale_Duloxetine_47